NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Daré Bioscience (NASDAQ: DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive health. Daré's lead product candidate, Ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.
On July 16th, the company announced that it has entered into an asset transfer agreement with Hydra Biosciences, Inc. for the transfer of all of Hydra's interest in certain intellectual property relating to Hydra's CatSper ion channel target portfolio.
DARE upcoming milestones, catalysts and analysts target READ MORE.
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/dare-bioscience/
As per management, CatSper represents a novel target for non-hormonal contraceptives for both men and women. Inhibiting CatSper prevents sperm from achieving the hyperactive motile state required for fertilization. The potential for a first-in-class non-hormonal male or female contraceptive option aligns with the objectives of the foundations and government agencies that fund contraceptive research, and as such the company will be pursuing grant funding to support the near-term research.
DARE clinical progress and market analysis READ MORE.
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/dare-bioscience/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source
